Cytokinetics, Inc.

Smithkline Beecham Corporation

Glaxosmithkline LLC

Cancer Research Technology Limited

Glaxosmithkline Intellectual Property Development Limited

Nicholas D Adams

Steven David Knight

Dashyant Dhanak

Cynthia A Parrish

Gustave Bergnes

David John Morgans, Jr

Xiangping Qian

Han-Jie Zhou

Hong Jiang

Bradley Paul Morgan

Luke W Ashcraft

Kevin J Duffy

Bing Yao

Jianchao Wang

Duke Fitch

Rosanna Tedesco

Andrew I McDonald

Jennifer Kuo Chen Huang

Kenneth Allen Newlander

Alexander Joseph Reif

Amita M Chaudhari

Kenneth Wiggall

Christopher Joseph Aquino

Stanley J Schmidt

Jonathan Michael Ghergurovich

Martha A Sarpong

Terence John Kiesow

Jerry Leroy Adams

William Henry Miller

Juan I Luengo

Allan Michael Jordan

Joelle Lorraine Burgess

Jeffrey Michael Axten

Domingos J Silva

Stuart Paul Romeril

Jun Tang

Bryan Wayne King

Bohdan Waszkowycz

Jonathan M Ghergurovich

Andrew B Benowitz

Mei Li

David T Fosbenner

Michael Gerard Darcy

Toshihiro Hamajima

Carla A Donatelli

Lance Howard Ridgers

Karen Anderson Evans

Ali Raoof

Christopher S Kershaw

Kristin M Goldberg

Roger J Butlin

María Lourdes Rueda Benede

Martha Sarpong

Lance Ridgers

The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Y, X, X, R, R, R, Rand Rare as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Substituted pyridines as inhibitors of DNMT1

This invention relates to the use of triazolone derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.

Triazolones as fatty acid synthase inhibitors

This invention relates to the use of triazolone derivatives of Formula (I) for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of triazolones in the treatment of cancer.

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.

Imidazole-benzamide anti-cancer agents

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.

Quinoline derivatives as P13 kinase inhibitors

Imidazopyridinyl benzamide mitotic kinesin inhibitors

Provided are compounds of Formula V and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders. 

Imidazoyl-benzamide anti-cancer agents

Imidazopyridinyl-benzamide anti-cancer agents

Provided are compounds of Formula I and pharmaceutically acceptable salts thereof which may be useful for the treatment of cancer or other proliferative disorders. 

Provided herein are certain substituted N-phenethylbenzamide of formula V: that may be useful for treating certain cellular proliferation diseases and disorders by modulating the activity of CENP-E.

N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases

The present invention relates to a compound represented by Formula (I): and pharmaceutically acceptable salts. Compounds of the present invention inhibit Aurora kinase, making them especially suitable for the treatment of a number of diseases, including solid tumor cancers and hematological cancers.

Azaindole inhibitors of aurora kinases

Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed.

Compounds, methods and compositions

Growing community of inventors

Philadelphia, PA, United States of America

Nicholas D Adams